Disease overview

Alterations

177

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

356

Natural agents

Natural products

Merged ranked

418

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Inevitable progressive neurodegeneration in all carriers of HTT CAG expansion >36 repeats; no spontaneous remission; motor, cognitive, psychiatric decline universally progressive

Best-intervention remission

Tetrabenazine/deutetrabenazine (VMAT2 inhibitors): 25-30% reduction in chorea score (FIRST-HD); no disease-modifying treatment proven; genetic CSF biomarker (mutant huntingtin, mHTT) reduction achieved with tominersen ASO — but Phase 3 halted 2021 (higher dose harmful); lower-dose tominersen now in Phase 2/3 after exploratory biomarker signal

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large — no approved disease-modifying treatment; symptomatic treatment only

Primary barrier

biological

Barrier detail: HD is unique in having a perfectly predictive genetic test allowing pre-symptomatic intervention — the challenge is that trials of mHTT-lowering agents (tominersen, WVE-003) have faced setbacks; the therapeutic window (pre-manifest vs manifest disease) and appropriate dose remain unclear; genetic counselling for presymptomatic testing is complex

Last SoC change: 2023 — valbenazine (Ingrezza) exploring HD chorea; 2021 tominersen Phase 3 halted (unexpectedly worse in higher-dose arm); 2017 deutetrabenazine (Austedo) approved for HD chorea; 2008 tetrabenazine approved; no disease-modifying treatment since disease characterised

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0007739 · ORPHA: ORPHA:399

Alterations

Showing 80 of 177 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormal cerebral white matter morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal circulating cholesterol concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Abnormal involuntary eye movements	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal libido	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of eye movement	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the sense of smell	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormally slow thought process	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Addictive alcohol use	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Aggressive behavior	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Agitation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anger	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anxiety	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Apathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ataxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Atypical behavior	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Babinski sign	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Bradykinesia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Broad-based gait	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Caudate atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebellar atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebellar vermis atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebral atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Choking episodes	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chorea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Clonus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Clumsiness	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Compulsive behaviors	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Decreased body mass index	Scales & PROs	Clinical scale	—	—	Moderate	HPO, Monarch	HPO
Degeneration of the striatum	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Delusion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dementia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Depression	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Disinhibition	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dystonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Excessive daytime somnolence	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gait ataxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gait disturbance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gait imbalance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Generalized muscle weakness	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Gliosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hallucinations	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperactivity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperreflexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypokinesia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Impaired visuospatial constructive cognition	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Inability to walk	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Insomnia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Involuntary movements	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Irritability	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Memory impairment	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Mental deterioration	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Mutism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myoclonus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neuronal loss in basal ganglia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neuronal loss in central nervous system	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Oculomotor apraxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Oral motor hypotonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Oral-pharyngeal dysphagia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Personality changes	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polyphagia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Poor fine motor coordination	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Progressive cerebellar ataxia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Rigidity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Seizure	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Speech articulation difficulties	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Staring gaze	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Suicidal ideation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ventriculomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ADRA2A adrenoceptor alpha 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2B adrenoceptor alpha 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2C adrenoceptor alpha 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOE apolipoprotein E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATXN3 ataxin 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BDNF brain derived neurotrophic factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD4 CD4 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD8A CD8 subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNR1 cannabinoid receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4 cytochrome c oxidase associated subunit FA4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4L2 cytochrome c oxidase hypoxia associated subunit FA4L2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACEBUTOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETOPHENAZINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ADAPALENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADUCANUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMINEPTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMISULPRIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMOXAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANTI-THYMOCYTE GLOBULIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APIXABAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
APRACLONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARIPIPRAZOLE LAUROXIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARSENIC TRIOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BACLOFEN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENPERIDOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZQUINAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZQUINAMIDE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAXOLOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BLONANSERIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BREXPIPRAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BRIMONIDINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMPERIDOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUPROPION HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSPIRONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANNABIDIOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPSAICIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
CREATINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DALZANEMDOR	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LATREPIRDINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
OLANZAPINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PRIDOPIDINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RILUZOLE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TIAPRIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TOMINERSEN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VOTOPLAM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
AMANTADINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ANX-005	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ATOMOXETINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BEVANTOLOL HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BIOTIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BRANAPLAM	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CYSTEAMINE BITARTRATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DIVALPROEX SODIUM	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
GLYCEROL PHENYLBUTYRATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LAQUINIMOD	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LITHIUM CARBONATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MARDEPODECT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MAVOGLURANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MEMANTINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
NEFLAMAPIMOD	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
PEPINEMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SODIUM PHENYLBUTYRATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SRX246	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
THIAMINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TRIHEPTANOIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ALENDRONATE SODIUM	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACEBUTOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETOPHENAZINE MALEATE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ADAPALENE Repurposing via BDNF	Small molecule	Approved	Strong	95	—	DGIdb	—
ADUCANUMAB Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
AMINEPTIN Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
AMISULPRIDE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing via BDNF	Small molecule	Approved	Strong	95	—	DGIdb	—
AMOXAPINE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANTI-THYMOCYTE GLOBULIN Repurposing via CD4	Small molecule	Approved	Strong	95	—	DGIdb	—
APIXABAN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE HYDROCHLORIDE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
APRACLONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing via BDNF	Small molecule	Approved	Strong	95	—	DGIdb	—
ARIPIPRAZOLE LAUROXIL Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
ARSENIC TRIOXIDE Repurposing via BDNF	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE MALEATE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ATENOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing via DRD3	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
BACLOFEN Repurposing via BDNF	Small molecule	Approved	Strong	95	—	DGIdb	—
BENPERIDOL Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZQUINAMIDE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZQUINAMIDE HYDROCHLORIDE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAXOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BETHANIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BLONANSERIN Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
BORTEZOMIB Repurposing via BDNF	Small molecule	Approved	Strong	95	—	DGIdb	—
BREXPIPRAZOLE Repurposing via DRD2	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BRIMONIDINE TARTRATE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets

Natural Products

72 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Creatine Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Amino acid	Phase III	Emerging	16	6 trials View evidence Registry trials NCT01411163 — Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability (COMPLETED) PHASE2 NCT00712426 — Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) (TERMINATED) PHASE3 NCT01412151 — Creatine Safety & Tolerability in Huntington's Disease (COMPLETED) PHASE2 NCT00592995 — Creatine Safety and Tolerability in Premanifest HD: PRECREST (COMPLETED) PHASE2 NCT00026988 — Creatine Therapy for Huntington's Disease (COMPLETED) PHASE1, PHASE2 NCT01411150 — Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Meta Analysis, Review Efficacy of ethyl-EPA as a treatment for Huntington disease. Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto…	Nutraceutical	Phase III	Emerging	10	1 trials 1 Meta-analysis View evidence Registry trials NCT00146211 — TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Garlic Natural product Review Potential protective effects of pungent flavor components in neurodegen…	Food compound	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin C Natural product Human Study Pantothenate deficiency could lead to neurodegeneration/dementia in Hun… Review Role of vitamins in neurodegenerative diseases: a review.	Nutraceutical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin D3 Natural product Human Study Pantothenate deficiency could lead to neurodegeneration/dementia in Hun… Review Role of vitamins in neurodegenerative diseases: a review.	Nutraceutical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Curcumin Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Food compound	Preclinical	Emerging	7	5 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Food compound	Preclinical	Emerging	7	1 trials View evidence Registry trials NCT02336633 — Resveratrol and Huntington Disease (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Coenzyme Q10 Natural product Clinical trial publication Coenzyme Q10 supplementation in acute ischemic stroke: Is it beneficial… Clinical trial publication A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in… Clinical trial publication Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Hea…	Nutraceutical	Phase III	Emerging	7	3 trials 3 Trial pubs View evidence Registry trials NCT00980694 — Bioavailability of Ubiquinol in Huntington Disease (COMPLETED) PHASE1 NCT00920699 — Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) (COMPLETED) PHASE2 NCT00608881 — Coenzyme Q10 in Huntington's Disease (HD) (TERMINATED) PHASE3 Published literature Clinical trial publication Coenzyme Q10 supplementation in acute ischemic stroke: Is it beneficial in short-term administration? (Nutritional neuroscience, 2020) Clinical trial publication A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (Neurology, 2017) Clinical trial publication Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10 (Journal of Huntington's disease, 2012) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Melatonin Natural product Animal Study Melatonin inhibits cytosolic mitochondrial-DNA induced neuroinflammator… Animal Study Quercetin supplementation is effective in improving mitochondrial dysfu… Review Cellular mechanisms of melatonin: Insight from neurodegenerative diseas…	Nutraceutical	Preclinical	Emerging	7	1 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT04421339 — Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Creatine Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Amino acid	Phase III	Emerging	7	6 trials View evidence Registry trials NCT01411163 — Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability (COMPLETED) PHASE2 NCT00712426 — Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) (TERMINATED) PHASE3 NCT01412151 — Creatine Safety & Tolerability in Huntington's Disease (COMPLETED) PHASE2 NCT00592995 — Creatine Safety and Tolerability in Premanifest HD: PRECREST (COMPLETED) PHASE2 NCT00026988 — Creatine Therapy for Huntington's Disease (COMPLETED) PHASE1, PHASE2 NCT01411150 — Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ashwagandha Natural product Animal Study These results indicate immense potential of Withaferin A for the treatm… Review The review concludes the results of recent studies on Ashwagandha sugge… Review Withania somnifera in neurological disorders: Ethnopharmacological evid…	Ayurvedic	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product Transgenic Animal Study Berberine could effectively alleviate motor dysfunction and prolong the…	Botanical	Preclinical	Emerging	7	5 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Black Seed Oil Natural product Animal Study Nano-formulated thymoquinone suspension can efficiently culminate 3-NP… In Vitro Study Resveratrol could be used to slow down Huntington's Disease progre…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Quercetin Natural product Meta Analysis, Review Efficacy of ethyl-EPA as a treatment for Huntington disease. Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Egcg Natural product Human In Vitro Neurorescue activity, APP regulation and amyloid-beta peptide reduction… Animal Study The polyphenol in green tea known as EGCG may inhibit the progression o…	Food compound	Phase II	Emerging	7	1 trials View evidence Registry trials NCT01357681 — Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ginseng Natural product Animal Study Ginsenosides offer a potential therapeutic choice for the treatment of… Review Effects of Panax ginseng in Neurodegenerative Diseases. Review Ginseng and its constituents have potential merits in the treatment of…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Bacopa Natural product Review Neuroprotection with Bacopa monnieri-A review of experimental evidence.	Ayurvedic	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Moringa Natural product Review Neuroprotective potential of Moringa oleifera mediated by NF-kB/Nrf2/HO…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Cannabidiol Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Food compound	Phase II	Emerging	2	1 trials View evidence Registry trials NCT01502046 — Neuroprotection by Cannabinoids in Huntington's Disease (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Licorice Natural product In Vitro Study Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregula…	Botanical	Preclinical	Emerging	2	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Ginseng (Asian) Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cannabinoids Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ginsenosides Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cannabis Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Delta-Tetrahydrocannabinol (THC) Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Chrysin Natural product Animal Study Chrysin ameliorates 3 nitropropinoic acid induced neurotoxicity targeti… Animal Study Chrysin can serve as a potential therapeutic agent on 3-Nitropropionic… Review The findings indicate that chrysin has protective effects against neuro…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Rutin Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Sesamol Natural product Animal Study Sesamol attenuates experimentally induced Huntington-like changes in an… Animal Study Sesamol protects against cognitive dysfunction and altered glutathione…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Piperine Natural product Review Potential protective effects of pungent flavor components in neurodegen… In Vitro Study The results of the current study reveal the neuroprotective competency…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Vitamin B-5 (Pantothenic Acid) Natural product Human Study Pantothenate deficiency could lead to neurodegeneration/dementia in Hun… Review Role of vitamins in neurodegenerative diseases: a review.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Catechin Natural product Human In Vitro Neurorescue activity, APP regulation and amyloid-beta peptide reduction…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
6-Shogaol Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ellagic Acid Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Betulinic Acid Natural product Animal Study Betulinic acid hydroxamate has the potential for further pharmacologica…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Carbon 60 Natural product Insect Study Fullerenols prevent neuron death and reduce oxidative stress in drosoph…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ginseng (American) Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ginseng (Korean) Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Goji Natural product Human Study Creatine reduces oxidative injury to DNA in patients with Huntington&#0… Human Study Eiocosapentaenoic acid significantly reduces brain atrophy in Huntingto… Human Study Improved Executive Function and Callosal White Matter Microstructure af…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Guarana Natural product Animal Study Guarana hydroalcoholic extract has therapeutic potential in combating a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Naringenin Natural product Animal Study Naringenin mitigates behavioral alterations and provides neuroprotectio…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Ligustrazine Natural product Animal Study Neuroprotective activity of tetramethylpyrazine against 3-nitropropioni… Transgenic Animal Study Neuroprotective effect of aloe emodin against Huntington's disease… Animal Study Neuroprotective potency of mangiferin against 3-nitropropionic acid ind…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Emodin Natural product Animal Study Neuroprotective activity of tetramethylpyrazine against 3-nitropropioni… Transgenic Animal Study Neuroprotective effect of aloe emodin against Huntington's disease… Animal Study Neuroprotective potency of mangiferin against 3-nitropropionic acid ind…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Mangiferin Natural product Animal Study Neuroprotective activity of tetramethylpyrazine against 3-nitropropioni… Transgenic Animal Study Neuroprotective effect of aloe emodin against Huntington's disease… Animal Study Neuroprotective potency of mangiferin against 3-nitropropionic acid ind…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Perillaldehyde Natural product Animal Study Perillaldehyde alleviates polyQ-induced neurodegeneration through the i…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Safranal Natural product Animal Study Safranal prevented the motor dysfunction induced by 3-NP in animal mode…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product Human In Vitro Neurorescue activity, APP regulation and amyloid-beta peptide reduction… Animal Study The polyphenol in green tea known as EGCG may inhibit the progression o…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
False Black Pepper Natural product Animal Study These findings suggest the neuroprotective effect of embelin against Hu…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ruta Graveolens Natural product Review Ruta graveolens as a potential source of neuroactive compounds to promo…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Amla Fruit Natural product Review A review exploring the multifaceted neuroprotective actions of amla.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Astaxanthin Natural product In Vitro Study Astaxanthin has protection against neuronal excitotoxicity.	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Baicalein Natural product Review Baicalein-mediated regulation of Nrf2/ARE, NFĸB, and MAPK signaling in…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carnosic Acid Natural product Review Carnosic acid is a potential candidate to be listed as a neuroprotectiv…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rosmarinic Acid Natural product In Vitro Study Discovery of natural compounds as nonpeptidyl inhibitors is a significa…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cottonseed Oil (Gossypol) Natural product In Vitro Study Gossypol induces autophagic degradation of mutant huntingtin.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Raspberry Natural product In Vitro Study Identification and microbial production of the raspberry phenol salidro…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Plantarum Natural product In Vitro Study L. plantarum 200655 might be used as a prophylactic functional ingredie…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bamboo Natural product In Vitro Study Lig-8, a compound extracted from bamboo, exhibits neuroprotective prope…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Icariin Natural product Review Mechanistic perspectives of icariin against neuroinflammation.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lotus Natural product In Vitro Study Neferine attenuates the protein level and toxicity of mutant huntingtin…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Caffeic Acid Phenethyl Ester Natural product Review Neuroprotective potential of caffeic acid phenethyl ester in CNS disord…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Capsaicin Natural product Review Potential protective effects of pungent flavor components in neurodegen…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Punicic Acid Natural product Review Punicic acid and its role in the prevention of neurological disorders.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Stilbenes Natural product Review Resveratrol: a natural compound with pharmacological potential in neuro…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Tauroursodeoxycholic Acid Natural product Review Tauroursodeoxycholic acid (TUDCA) may have therapeutic value in neurode…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Avocado Natural product Review The critical review results indicate that compounds in avocado are uniq…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Diosmin Natural product Review The neuroprotective effects of hesperidin and diosmin in neurological d…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hesperidin Natural product Review The neuroprotective effects of hesperidin and diosmin in neurological d…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Carotenoids Natural product Review The neuroprotective potential of carotenoids in vitro and in vivo.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fisetin Natural product In Vitro Study The polyphenols fisetin and resveratrol provide neuroprotection in mult…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Flavonoids Natural product Review The potential of flavonoids for the treatment of neurodegenerative dise…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Myricetin Natural product Review Therapeutic potential of myricetin in the treatment of neurological, ne…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Garlic: Aged Natural product In Vitro Study This experimental data provides information for the molecular targets o…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network